Clinical TrialNov 6, 2026, 11:11 AM
Evaxion A/S: Phase 2 data show strong immune response from EVX-01 cancer vaccine
AI Summary
Evaxion A/S announced new biomarker data from its phase 2 trial for the personalized cancer vaccine EVX-01 in patients with advanced melanoma. The data demonstrate strong immune responses induced by EVX-01 and further validate the company's AI-Immunology™ platform. The findings, which include the detection of neoantigen-specific T-cells and a strong correlation between AI predictions and actual T-cell responses, will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. This new data supplements previous three-year results showing high vaccine target precision and sustained responses.
Key Highlights
- Evaxion A/S announces new biomarker data from phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma.
- Data shows potent EVX-01 induced immune responses and validates Evaxion's AI-Immunology™ platform.
- New findings include detection of EVX-01 induced neoantigen-specific T-cells directly ex vivo.
- Significant association (p<0.001) between AI-Immunology™ predictions and actual T-cell responses.
- Phase 2 trial previously showed 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up.
- EVX-01 is a personalized peptide-based cancer vaccine targeting tumor-specific neoantigens.
Price Impact
More from EVAX